Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q1 2024 (March 31)8holders
$1.15avg. 13F price*
At the end of Q1 2024, 8 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings. The largest holders were Opti Capital Management, LP ($33.4M), Nomura Holdings Inc. ($10.1M) and New York State Common Retirement Fund ($4.9M).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $38.1M |
| Exits | 3 | $11.4M |
Ownership 8 holders
| Opti Capital Management, LP | 2.56% | New | 35,500,000 | $33.4M |
| Nomura Holdings Inc. | 0.08% | Reduce -12.7% | 67,606 | $10.1M |
| New York State Common Retirement Fund | 0.01% | Reduce -12.7% | 5,263,000 | $4.9M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | New | 4,950,000 | $4.7M |
| Liberty Mutual Group Asset Management Inc. | 0.41% | No change | 1,525,000 | $1.4M |
| Bank of New York Mellon Corp | 0.00% | No change | 600,000 | $566K |
| Sei Investments Co. | 0.00% | No change | 99,000 | $93K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 3,000 | $3K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.